ISSN 2326-7283
African Journal of Internal Medicine Vol. 1 (1), pp. 010- 016, 2012. © International Scholars Journals
Full Length Research Paper
Autologus MSC bone marrow stem cell and allogenic pancreatic stem cell for repair of beta pancreatic cell in experimental diabetes mellitus
Purwati Armand1,2, Fedik. A. R2, Sony Wibisono1, Anas. P2, Eric. H2, Helen. S2, Deya. K2
1Department of Internal Medicine, Faculty of Medicine, Airlangga University –Dr. Soetomo Hospital, Surabaya, Indonesia.
2Stem Cell Laboratory, Institute of Tropical Diseases, Airlangga University, Surabaya, Indonesia.
*Corresponding author. E-mail: [email protected]
Received 23 October, 2012; Accepted 19 December, 2012
Abstract
Alternative therapies in diabetes mellitus (DM) management include the use of stem cells. Stem cells derived from the bone marrow and pancreatic cells from allogenic donors were used in this experimental animal model to restore glucose control. DM was induced in Wistar rats with 50 mg/kg alloxan. DM rats were divided into 4 treatment groups, Group 1 was transplanted with autologous bone marrow derived mesenchymal stem cells (MSC) by intraperitoneally injection. Group 2 was given allogenic pancreatic cells intraperitoneally. Group 3 was given insulin subcutaneously, and Group 4 served as control (no treated). The dosage was 200,000 cells/rat. Post therapy results in group 1 revealed significant decrease of blood sugar levels, an increase in insulin levels, and increased C peptide levels. In group 2, there were more pronounced changes, improvements in glucose control compared to group 1. Those receiving only insulin the levels of blood sugar decreased but less so compared to those receiving MSC or pancreatic cells (p = 0.002). In a DM Wistar rat model the intraperitoneal administration of pancreatic cells resulted in better restoration of glucose control than intraperitoneally of bone marrow derived MSC, which in turn was better than only insulin.
Key words: Diabetes mellitus (DM), stem cell, allogenic, autologous.